Eli Lilly reported third-quarter revenue of $24.4 billion, up 39% year over year and above analyst expectations of about $22.6 billion.
Adjusted earnings were $7.48 per share, also ahead of forecasts. Strong demand for diabetes drug Mounjaro and obesity drug Zepbound drove results.
Lilly raised its 2026 revenue forecast to $91–$92 billion, from $85–$87 billion—the third consecutive quarterly increase to its full-year outlook.
The company’s updated non-GAAP earnings guidance is $35–$36 per share, lower than its previous $35.50–$36.50 range, reflecting acquisition-related research charges.
Sources:
Lilly reports third-quarter 2026 financial results, raises full ...
Eli Lilly lifts revenue outlook as weight-loss shot demand ...
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
[PDF] Immediately Refer to: Megan MacCauley; maccauley_megan@lilly ...
Eli Lilly shares jump 6% as drugmaker lifts 2026 revenue ...
Earnings call transcript: Eli Lilly beats Q3 2026 estimates ...
Stock market today: Live updates
Lilly Lifts Sales Outlook on GLP-1 Demand, Trims EPS
Eli Lilly (LLY) Q3 2026 Earnings Call Transcript & Audio
Lilly Q3 Profit Rises 16%; Lifts FY26 Sales View, Trims Adjusted Earnings Outlook
Earnings live updates: Eli Lilly stock pops as strong GLP-1 ...
Eli Lilly (LLY) revenue jumps 39% as it raises its 2026 sales forecast.